A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection

Urology

Volumn 51, Issue 4, 1998, Pages 610-615

  Klimberg, Ira W ^a   Cox II, Clair E ^b   Fowler, Cynthia L ^b   King, William ^b   Kim, Sun Sook ^b   Callery D'Amico, Susan ^b  

^a Urology Center of Florida   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; LEVOFLOXACIN; LOMEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTI-INFECTIVE AGENTS, URINARY; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; QUINOLONES; URINARY TRACT INFECTIONS;

EID: 0031923784     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00708-5     Document Type: Article

References (14)

1. Stamm WE, and Hooton TM: Management of urinary tract infection in adults. N Engl J Med 329: 1328-1334, 1993.
2. Hooton TM: A simplified approach to urinary tract infection. Hosp Pract (Off Ed) 30: 23-30, 1995.
3. Falagas ME, and Gorbach SL: Practice guidelines: urinary tract infections. Infect Dis Clin Pract 4: 241-257, 1995.
4. Kunin CM: Urinary tract infections in females. Clin Infect Dis 18: 1-12, 1994.
5. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, and Rosenthale ME: In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 36: 860-866, 1992.
6. Davis R, and Bryson HM: Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47: 677-700, 1994.
7. Anonymous: Levofloxacin data presented to the National Committee on Clinical Laboratory Standards (NCCLS) Subcommittee on Antimicrobial Susceptibility Testing, January, 1996. Data on File, R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey, 1996.
8. Rubin RH, Shapiro ED, Andriole VT, Vincent T, Davis RJ, and Stamm WE: Evaluation of new anti-infective drugs for the treatment of urinary tract infections. Clin Infect Dis 15(suppl 1): 216-227, 1992.
9. Terpenning MS, Bradley SF, Wan JY, Chenoweth CE, Jorgensen KA, and Kauffman CA: Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc 42: 1062-1069, 1994.
10. Ena J, Amador C, Martinez C, and Ortiz de la Tabla V: Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 153: 117-120, 1995.
11. Thomson KS, Sanders WE, and Sanders CC: USA resistance patterns among UTI pathogens. J Antimicrob Chemother 33(suppl A): 9-15, 1994.
12. Stamm WE: Approach to the patient with urinary tract infection, in Gorbach SL, Bartlett JG, and Blacklow NR (Eds): Infectious Diseases. Philadelphia, WB Saunders, 1992, pp 788-798.
13. Correia O, Delgado L, and Barros MA: Bullous photodermatosis after lomefloxacin. Arch Dermatol 130: 808-809, 1994.
14. Lowe NJ, Fakouhi TD, Stern RS, Bourget T, Roniker B, and Swabb EA: Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing. Clin Pharmacol Ther 56: 587-591, 1994.